Objective To determine whether a moderate-to-large patent ductus arteriosus (PDA) is responsible for vasopressordependent hypotension, occurring at the end of the first postnatal week.
Infants born extremely preterm frequently develop a moderate-to-large PDA at the end of the first week. When other identifiable causes of hypotension have been ruled out, clinicians often attribute the cause of vasopressor-dependent hypotension to the presence of a PDA (disregarding the possible involvement of any of the nonspecific causes mentioned previously). Although it is true that a moderate-to-large PDA can lower systemic blood pressure (BP) [14] [15] [16] and is associated with the presence of vasopressor-dependent hypotension at the end of the first week, 13, 17 no study to date has determined whether the PDA actually is responsible for the vasopressor-dependent hypotension or whether its presence is just a surrogate for nonspecific causes related to immaturity/illness.
Indomethacin, given either prophylactically (within 24 hours of birth) or within the first few days after birth, is effective in achieving ductus closure. 18 Although more than 20 randomized controlled trials (RCTs) have investigated the effects of early PDA treatment on neonatal morbidities, none have mentioned its effect on the incidence of vasopressor-dependent hypotension. 18, 19 Therefore, we performed the following retrospective double cohort controlled study to examine whether early treatment of the PDA decreases the incidence of vasopressor-dependent hypotension at the end of the first postnatal week.
Before May 2011, all infants in our nursery who delivered at ≤27 +6 weeks' gestation were treated with prophylactic indomethacin ([PINDO] epoch). After April 30, 2011, PINDO was no longer used, and infants were only treated with indomethacin if the PDA persisted beyond 7 days (conservative epoch; see Methods). In the following study, we hypothesized that infants treated with PINDO would have a lower incidence of vasopressor-dependent hypotension at the end of the first week and that closure of the moderate-to-large PDA would explain this effect.
Methods
This project was approved by the institutional review board of the University of California San Francisco. Infants were included in the study if they were born between January 2004 and December 2015, delivered at ≤27 +6 weeks' gestation, and were admitted to the intensive care nursery at the University of California San Francisco within 24 hours of birth. Detailed descriptions of our approach to respiratory and hemodynamic support have been published previously. [20] [21] [22] Two distinct epochs of PDA management existed during this 12-year period. During the first epoch, before May 2011, all infants without contraindications (n = 284) were treated with a course of PINDO starting within 15 hours of birth. Six potential PINDO doses were given at 24-hour intervals. An echocardiogram was performed before the third PINDO dose, and doses 4-6 were given only if there was any evidence (even minimal) of ductus patency on the echocardiogram. An echocardiogram was repeated at the end of the first week. Following the PINDO treatment, infants with a small or closed ductus were examined daily for a change in clinical symptoms indicative of a PDA (systolic murmur, widened pulse pressure, hyperdynamic precordium). If any of these occurred, an echocardiogram was performed within 24 hours. Infants with a persistent moderate-to-large PDA after the first week were followed to determine if or when retreatment or ligation would be necessary.
In May 2011, we made a change to a more conservative treatment approach. During epoch 2 (May 2011 through December 2015, n = 127) PINDO was no longer used. PDAs were no longer treated with indomethacin until at least 8 days of age to allow for spontaneous closure. 23 During epoch 2, all infants had an echocardiogram on postnatal days 6 or 7.
Our goal was to determine whether a moderate-to-large PDA was responsible for vasopressor-dependent hypotension at the end of the first postnatal week if other identifiable causes of hypotension were excluded. Therefore, infants who died or developed identifiable causes of hypotension (bacteremia, NEC, or spontaneous intestinal perforations) during the first 7 days were excluded from our study population (Table I) . None of the study infants underwent surgical ligation during the first 7 postnatal days. The effects of a moderate-to-large PDA (and of the 2 different treatment approaches) on other shortterm and long-term neonatal morbidities will be reported separately.
A single neonatologist prospectively evaluated and recorded all of the perinatal/neonatal risk factors during the hospitalization (Table I) . Gestational age was determined by the date of last menstrual period and early ultrasound scans (before 24 weeks' gestation). Small for gestational age was defined as birth weight less than the 10th percentile for gestational age via use of the growth curves from Olsen et al. 24 All infants were examined with serial bedside cranial ultrasound scans initiated within the first week of life. Intraventricular hemorrhage was classified with the 4-level grading system. 25 The echocardiographic studies included 2-dimensional imaging, M-mode, color flow mapping, and Doppler interrogation as previously described. 26 A moderate-to-large PDA was defined by one or more of the following echocardiographic criteria: internal ductus diameter ≥ 1.5 mm (or PDA:left pulmonary artery ≥ 0.5); ductus flow velocity ≤ 2.5 m/s or mean pressure gradient across the ductus ≤ 8 mm; left pulmonary artery diastolic (or mean) flow velocity > 0.2 (or > 0.42) m/s; and/or reversed diastolic flow in the descending aorta. 22, 27 During the time period of our study, a standardized approach was used in our nursery that determined when volume expanders and vasopressors would be initiated and included the rate at which they would be increased or decreased (see below). 21 An arterial line and transducer were used to measure BP continuously in all infants receiving dopamine infusions or hydrocortisone for BP support.
Hypotension was defined as "mean BP less than the third percentile for postmenstrual age that lasted more than 15 minutes." 28, 29 Operationally, this meant that infants were considered to be hypotensive, and require treatment for their hypotension, if their mean BP was less than ([postmenstrual age in mm Hg] -[3-4 mm Hg]).
When infants failed to maintain an adequate BP (defined as "BP greater than the hypotensive range"), no more than 2 fluid boluses could be given initially to correct presumed hypovolemia. If the fluid boluses were unsuccessful in maintaining an adequate BP, dopamine support could be added. Infusion of dopamine was started at a rate of 5 mg/kg/min. The dose could be increased by 2 mg/kg/min every 15-30 minutes until an adequate BP was achieved. If a dopamine infusion rate of >15 mg/kg/min failed to maintain an adequate BP, hydrocortisone (starting at 1 mg/kg/d, dosed at 0.25 mg/kg/dose every 6 hours) could be added. When attempting to wean the dopamine infusion, the rate was decreased by 2 mg/kg/min every hour as long as an adequate BP was maintained.
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Dopamine infusion rates were recorded hourly for the first 7 days after birth. Our outcome, vasopressor-dependent hypotension at the end of the first week, was defined as having received vasopressors for at least 24 hours during postnatal days 4-7 (noncontiguous; maximum 96 hours) (day of birth = postnatal day 0). Postnatal days 4-7 were chosen because (1) PDAs that respond to PINDO are small or closed by postnatal day 4; (2) most of the factors specifically related to hypotension during the early transitional period are no longer present by postnatal day 4 12 ; and (3) indomethacin treatment could be used in the conservative epoch after postnatal day 7.
The severity of the hypotension was determined by the maximum amount of dopamine that was used for at least 24 hours (any, ≥6, or ≥10 mg/kg/min). The primary outcome was the incidence of dopamine-dependent hypotension, defined as ≥6 mg/kg/min dopamine for at least 24 hours during postnatal days 4-7. Hydrocortisone administration was counted as 24 hours of vasopressor exposure for each day it was given.
The mode of ventilation (continuous positive nasal airway pressure, biphasic nasal ventilation, or intubated mechanical ventilation), mean airway pressure, and fraction of inspired oxygen (FiO2) were recorded at noon each day for the first 7 days after birth. The mean airway pressure and FiO2 at the end of the first postnatal week (days 4-7) were calculated by averaging the daily mean airway pressures and FiO2 for days 4-7. For each infant, a daily respiratory severity score (RSS = mean airway pressure × FiO2) was calculated and averaged for days 4-7. A weighted mode of ventilation score was created to reflect the duration of different levels of respiratory support during 2 tests were used to compare the PINDO and vasopressor-dependent hypotension groups with categorical variables. For continuous variables, Student t tests were used to compare groups for parametric variables and Wilcoxon rank sum tests to compare groups for nonparametric variables.
Logistic regression was used to examine the relationship between PINDO and vasopressor-dependent hypotension. Treatment with PINDO was assigned by epoch and therefore not confounded by indication. Although 16 study infants born during the PINDO epoch received their first dose of indomethacin after 24 hours (on days 2 or 3, because of initial oliguria, elevated creatinine, or coagulopathy), all infants born during the PINDO period were analyzed with the intentionto-treat principle. Because several differences in baseline characteristics existed between the 2 epochs that might affect the outcomes (Table I) , we created 2 models: a simple (unadjusted) model (including only indomethacin treatment and outcome) and a model that included all the characteristics that differed significantly (with P values <.05) between the epochs (delivery room intubation, surfactant, RSS at 24 hours after birth, gestational diabetes, and male sex [ Table I] ). Sensitivity analysis was used to compare these models. Potential outcomes estimation with STATA's margins command was used to estimate a risk difference.
To examine whether closing the PDA with PINDO was effective in preventing hypotension among infants who were at the greatest risk for developing vasopressor-dependent hypotension, we used logistic regression to develop a model for predicting which infants would be most likely to develop vasopressor-dependent hypotension (assuming the infants had not received indomethacin previously to close their PDA). Therefore, to develop the model, we only used infants from the conservative epoch, because they had not received indomethacin previously to close their PDA. Baseline characteristics associated with vasopressor-dependent hypotension (with P values of ≤.10), were included in the model via the use of forward selection. The final variables included in the model were gestational age, dopamine ≥6 mg/kg/min for at least 12 hours during the first 24 hours of life, small for gestational age, RSS >2.5 at 24 hours of life, and an interaction term between gestational age and dopamine ≥6 mg/kg/min for at least 12 hours during the first 24 hours of life.
Hosmer-Lemeshow goodness of fit testing was used to assess calibration and the receiver operating characteristic was used to assess discrimination. The model fit the data well, and the area under the receiver operating characteristic curve was 0.89. We then used the model to predict the probability of vasopressor-dependent hypotension for each of the infants in the conservative and PINDO groups and used the c 2 test to compare a subset of infants from the 2 groups who had a high-predicted probability of vasopressor-dependent hypotension (probability ≥0.6).
Linear regression was used to examine the effects of PINDO on respiratory variables (mean airway pressure, FiO2, RSS, and mode of ventilation score) on days of life 4-7. The models included all the characteristics that differed between the PINDO and conservative epochs (see Table I ) and were checked to make sure they satisfied the assumptions of linear regression. Robust SEs were used to satisfy the constant variance assumption. Linear prediction was used to predict marginal means with STATA's margins command.
Results
During the study period, 411 infants were born; 98 infants were excluded because of NEC, early-onset septicemia, or death during the first 7 days (29 in the conservative group; 69 in the PINDO group) ( Table I) . The 2 treatment epochs were similar except for the incidences of gestational diabetes, male sex, surfactant administration, intubation in the delivery room, and RSS at 24 hours after birth ( Table I) . As expected, the incidence of moderate-to-large PDA at the end of the first week differed significantly between the 2 treatment epochs ( Table I) .
Infants in the PINDO group had a lower incidence of vasopressor-dependent hypotension than those in the conservative group (Tables II-IV and Figures 1 and 2; Table III and Figures 1 and 2 available at www.jpeds.com). As the severity of the vasopressor-dependent hypotension increased, the effects of PINDO became more significant (Tables II and IV and Figure 1 ). For our primary outcome of vasopressor-dependent hypotension (≥6 mg/kg/min of dopamine for at least 24 hours between days 4 and 7), we created 3 logistic regression models to evaluate whether the effects of PINDO on vasopressordependent hypotension were mediated through possible confounders that differed between the treatment epochs ( Table IV) Table IV) . This finding suggests that the effects of PINDO on vasopressor-dependent hypotension were not confounded by any of the differences in baseline characteristics.
During both treatment epochs, infants who had a persistent moderate-to-large PDA had an increased incidence of vasopressor-dependent hypotension (Table V) . When the variable "presence of a moderate-to-large PDA" was added to the adjusted model, the "presence of a moderate-to-large PDA" continued to be highly associated with the incidence of vasopressordependent hypotension (Model 3: OR = 0.3.38, 95% CI 1.32-8.60); in contrast, PINDO treatment no longer was associated significantly with vasopressor-dependent hypotension (Model (Table IV) , which suggests that the effect of PINDO on vasopressor-dependent hypotension is mediated through closure of the PDA. We examined whether closing the PDA with PINDO was effective in preventing hypotension in the subset of infants with a high predicted probability (probability ≥0.6) for developing vasopressor-dependent hypotension (see Methods). Even in this high probability subset, PINDO significantly decreased the incidence of vasopressor-dependent hypotension (incidence of vasopressor-dependent hypotension ≥6 mg/kg/ min of dopamine for at least 24 hours between days 4-7: PINDO group = 44%; conservative group = 85% [P = .02]).
In addition to its effects on hypotension, we also examined the effects of PINDO on the need for respiratory support at the end of the first postnatal week (days 4-7) ( Table VI) . Infants in the PINDO group required less mean airway pressure and had a lower RSS and weighted mode of ventilation score than those in the conservative group. The effects of PINDO were no longer significant when the presence of a moderate-to-large PDA was included in the model (Table VI) .
Discussion
We found that PINDO decreases the incidence of vasopressordependent hypotension (and the degree of respiratory support needed) at the end of the first postnatal week when other identifiable causes of hypotension are not involved. The majority of PINDO's effects can be attributed to its ability to close the moderate-to-large PDA that is present at the end of the first week. From our study, it is not possible to determine whether the PDA-induced hypotension is attributable to the shunt runoff into the low resistance pulmonary vascular bed 14 or to the increased mean airway pressure needed to overcome the PDAinduced changes in lung compliance. 30 Even though PINDO decreased the incidence of vasopressor-dependent hypotension, the incidence was not reduced to 0% (Tables II and V and Figure 1) . We speculate that nonspecific causes associated with immaturity and/or illness (eg, dysregulated cytokine, vasodilator, and/or cortisol production or release, delayed maturation of central autonomic or peripheral nervous systems) may be responsible for the vasopressor-dependent hypotension that occurs despite PDA closure. 13, 31 There are several limitations to our study. We used data from a single center; because the definition and treatment thresholds for hypotension differ by center, 5,10,11 our results may not be generalizable to centers in which hypotension is defined and managed differently. The effect size of PINDO on vasopressordependent hypotension may be less than our estimate in centers with stricter criteria for treatment of hypotension and greater in centers that treat hypotension liberally. In addition, even though we adjusted our analyses for differences between the epochs, there may have been unmeasured changes in practice that could have affected the rates of hypotension during the study period.
There are also strengths to our study. Previous observational studies that have tried to examine the relationship between the presence of a PDA and neonatal hypotension have been limited severely by the problem of residual confounding (ie, the presence of a PDA is also a likely surrogate for immaturity). Any study that just compares groups based on whether a PDA is present is significantly confounded by the fact that infants in the group with a persistent PDA also are significantly more immature than infants in the group with a closed ductus. In our study, PINDO was used as a surrogate instrument for PDA closure. The planned change in the use of indomethacin allowed us to use a retrospective double cohort controlled study design. With this study design, PINDO was not confounded by indication, as it has been in observational retrospective studies.
Approximately 92% of infants in our study closed their ductus after PINDO compared with only 36% of infants in the conservative group (Table I) . This imperfect correlation between PINDO and PDA closure does produce some misclassification because not all infants who received indomethacin closed their ductus and not all infants in the conservative group had a persistent moderate-to-large PDA. This type of misclassification, however, would bias our estimate towards the null, meaning that the true effect of PINDO is likely greater than what we observed in our study. The single-center aspect of the study meant that the same consensus-driven, standardized approaches to respiratory, hemodynamic, fluid, nutrition, and PDA evaluation and management were consistent among the infants in each of the study epochs. Although differences other than the use of PINDO administration did exist between the 2 time periods ( Table I ), models that included these factors produced similar ORs and CIs, suggesting that these factors were not confounders of the relationship between PINDO and vasopressor-dependent hypotension (Table IV) .
During the last decade, the use of prophylactic or early PDA treatment has decreased, 32 primarily because of the results of the prophylactic and early PDA treatment RCTs that failed to show any improvement in long-term morbidities (like bronchopulmonary dysplasia and neurodevelopment). 18, 19 Despite the lack of long-term benefits, the RCTs of PINDO have demonstrated important reductions in the risks of several shortterm morbidities like severe intraventricular hemorrhage, pulmonary hemorrhage, and surgical ligations. 18, 19 Our results suggest that PINDO or early PDA treatment has the additional short-term benefit of reducing the incidence of vasopressor-dependent hypotension. Decreasing the incidence of vasopressor-dependent hypotension is important because infants requiring vasopressor support are made nil per os and have more days of intravenous therapies, placing them at increased risk for infection. 33 There is also the possibility that vasopressor use may increase the risks of other morbidities. 3, 5, [34] [35] [36] Neonatologists may wish to consider these additional short-term benefits when they decide whether to use PINDO or early PDA treatment in infants born extremely premature. ■ 
